Watch the interview with CEO Tine Olesen below:
Biosergen discusses positive results in patients with deadly fungal infections
So far, the majority of patients involved in Biosergen’s proof-of-concept study for life-threatening fungal infections have been able to leave the hospital. This suggests the potential effect of BSG005 even at low doses. Moreover, the subscription period for the company’s TO3 warrants is approaching, which will take place between November 18 and 29. Listen to Tine Olesen, CEO, talk more about this.
Notes
Paxman reports strong growth
Aptahem publishes issuance documents
Novo Nordisk signs billion-dollar deal with Septerna
GSK buys liver disease drug
Fleries and Toleranzia merger approved
NEWSLETTER
NEWS
Lars Fruergaard Jørgensen leaves the CEO position at Novo Nordisk
Clinical progress and capital injection strengthen Alzinova's Phase II plans
BioStock Investor Pitch: Iconovo
Upcoming events!
Global Forum
Expand your understanding of new markets, striking global partnerships and attracting international capital. Find new opportunities and learn how to...
Investing in Life Science
We cover early-stage, growth-stage and late-stage investments. From business angels and seed investors driving medical breakthroughs, to investments empowering promising...
Life Science Summit
The Nordic region's leading forum for early-stage and growth-phase life science companies. The Summit bridges innovation and capital by providing...
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account
Chronicles
The first move has been made – now we are waiting for answers
Uncertainty makes it harder to deal
